What is Cellay?
Cellay, Inc. is at the forefront of developing Same Day OligoFISH Probes, which are chemically synthesized and labeled oligonucleotides engineered for exceptionally fast hybridization, completing in as little as 5-10 minutes. Leveraging cGMP manufacturing and isothermal processing, Cellay's products are designed to optimize and accelerate the FISH workflow for its clients. It is important to note that these probes are not FDA approved for cancer detection or diagnosis and are currently covered by pending patent applications. OligoFISH is a registered trademark of Cellay, Inc.
How much funding has Cellay raised?
Cellay has raised a total of $292K across 2 funding rounds:
Debt
$150K
Debt
$142K
Debt (2020): $150K with participation from PPP
Debt (2021): $142K led by PPP
Key Investors in Cellay
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Cellay?
With a substantial large-scale late-stage funding context, Cellay is poised for significant expansion and further development of its proprietary OligoFISH technology. The recent strategic investment suggests strong confidence from backers in the company's ability to scale its operations and potentially bring its innovative diagnostic tools to a broader market. Future efforts will likely focus on advancing patent applications, seeking regulatory approvals, and enhancing its market penetration within the life sciences and diagnostics sectors.
See full Cellay company page
